Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Peeva

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
The Journal of Allergy and Clinical Immunology|September 30, 2023
Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligoEmma Guttman-Yassky, Ester Del Duca, Joel Correa Da Rosa, et al.
The Journal of Investigative Dermatology|April 21, 2020
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled TrialSeth B Forman, David M Pariser, Yves Poulin, et al.
Clinical, Cosmetic and Investigational Dermatology|April 14, 2020
A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United StatesMichael Benigno, Kathryn P Anastassopoulos, Arash Mostaghimi, et al.
British Journal of Clinical Pharmacology|June 3, 2026
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participantsSrividya Neelakantan, Christopher Banfield, Kenneth Hung, et al.
The British Journal of Dermatology|March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group studyMegan N Landis, Stacy R Smith, Gabriel Berstein, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 14, 2025
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateSpencer I Danto, Mikhail Salganik, Anindita Banerjee, et al.
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2020
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateMichael F Robinson, Nemanja Damjanov, Bojana Stamenkovic, et al.
The Lancet. Rheumatology|January 27, 2024
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group studyChristopher Tehlirian, Elena Peeva, Elizabeth Kieras, et al.
Archives of Dermatological Research|July 18, 2024
Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligoYuji Yamaguchi, Elena Peeva, Ester Del Duca, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
The Journal of Allergy and Clinical Immunology|September 30, 2023
Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligoEmma Guttman-Yassky, Ester Del Duca, Joel Correa Da Rosa, et al.
The Journal of Investigative Dermatology|April 21, 2020
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled TrialSeth B Forman, David M Pariser, Yves Poulin, et al.
Clinical, Cosmetic and Investigational Dermatology|April 14, 2020
A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United StatesMichael Benigno, Kathryn P Anastassopoulos, Arash Mostaghimi, et al.
British Journal of Clinical Pharmacology|June 3, 2026
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participantsSrividya Neelakantan, Christopher Banfield, Kenneth Hung, et al.
The British Journal of Dermatology|March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group studyMegan N Landis, Stacy R Smith, Gabriel Berstein, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 14, 2025
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateSpencer I Danto, Mikhail Salganik, Anindita Banerjee, et al.
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2020
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateMichael F Robinson, Nemanja Damjanov, Bojana Stamenkovic, et al.
The Lancet. Rheumatology|January 27, 2024
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group studyChristopher Tehlirian, Elena Peeva, Elizabeth Kieras, et al.
Archives of Dermatological Research|July 18, 2024
Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligoYuji Yamaguchi, Elena Peeva, Ester Del Duca, et al.
Pageof 9